The expanded CAG repeat that causes HD sits within the very beginning of the huntingtin gene. Sometimes the huntingtin ...
A new Phase 1 study is testing SRP-1005, a huntingtin-lowering therapy given by injection under the skin. It’s early days, ...
In plain language. Written by scientists. From vision changes to genetic traffic jams and a clinical trial update, May was full of HD science excitement! Dive into our latest roundup to see how ...
We’re pleased to announce the 2026 HDBuzz Prize! This year, the HDBuzz Prize is brought to you by the Hereditary Disease ...
In plain language. Written by scientists. Vico Therapeutics have shared interim data about their drug, VO659, which targets the CAG expansion that causes several genetic diseases, including ...
Day 3 of #HD2026 put HTT under the microscope. Researchers shared new insights into HTT1a, next-generation HTT-lowering ...
In plain language. Written by scientists. Clinical trial data can drive discovery long after a study ends. Prilenia donated placebo-arm data from 2 HD clinical trials to CHDI, a valuable resource for ...
One of the biggest challenges in clinical research is making the most of the information that trials generate. A solution to this is to share data between stakeholders so that everyone can learn from ...
In plain language. Written by scientists. ⏱️10min read | Roche’s decision to stop development of 2 HTT-lowering programmes is disappointing, but the story doesn’t end there. Years of research answered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results